<DOC>
<DOCNO>en.2.319.463.2010.6.3</DOCNO>
<TITLE> Low doses to prevent diabetes </TITLE>
<TEXT>
 WASHINGTON, June 03 (bdnews24.com/reuters) - Low doses of GlaxoSmithKline's diabetes drug Avandia combined with metformin can prevent diabetes without causing the most common side-effects, Canadian doctors reported on Wednesday. Taking half a dose of Glaxo's combination pill reduced by two-thirds the risk that patients would go from having high blood sugar - pre-diabetes - to full type-2 diabetes, the researchers reported in the Lancet medical journal. 14 per cent of the patients treated with the drugs developed diabetes after four years, compared to 39 per cent of those given placebo, the researchers found. The effect would likely be the same with Avandia's rival drug in the same class, Takeda's Actos, said Dr Bernard Zinman of Mount Sinai Hospital at the University of Toronto, who led the study. 'I think it is a class effect,' Dr Zinman said in a telephone interview. Actos, known generically as pioglitazone and Avandia, known generically as rosiglitazone, belong to a class of drugs called thiazolidinediones, which help the body better use insulin. Avandia and Actos work well to help and even prevent diabetes. But they have side-effects, including fluid retention, heart failure and, possibly, heart attacks. Glaxo said this week it had settled more lawsuits alleging Avandia caused heart atta
</TEXT>
</DOC>
